Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523472 | 1.00 | JAK2 (0.40) | JAK2PTK2TLR8PIK3CDPIK3CG | |
| SCHEMBL521842 | 0.84 | JAK2 (0.42) | JAK2PTK2TLR8PIK3CDPIK3CG | |
| SCHEMBL521841 | 0.84 | JAK2 (0.42) | JAK2PTK2TLR8PIK3CDPIK3CG | |
| SCHEMBL520240 | 0.80 | KCNH2 (0.48) | JAK2PTK2KCNH2 | |
| SCHEMBL522076 | 0.79 | JAK2 (0.41) | JAK2PTK2KCNH2 | |
| SCHEMBL520743 | 0.77 | JAK2 (0.51) | JAK2PTK2PIK3CDPIK3CGPIK3CB | |
| SCHEMBL520742 | 0.77 | JAK2 (0.51) | JAK2PTK2PIK3CDPIK3CGPIK3CB | |
| SCHEMBL519748 | 0.75 | JAK2 (0.56) | JAK2PTK2PIK3CDPIK3CGPIK3CB | |
| SCHEMBL520688 | 0.73 | JAK2 (0.48) | JAK2PTK2PIK3CDPIK3CGPIK3CB | |
| SCHEMBL522554 | 0.73 | JAK2 (0.48) | JAK2PTK2PIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | JAK2 1/4885PTK2 592/4885TLR8 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.